Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Biorxiv : the Preprint Server for Biology
|
February 6, 2026
The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target
Zhiwei Ang, Annette Castro, Luca Paruzzo, et al.
Blood Cancer Discovery
|
July 2, 2024
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Federico Stella, Annalisa Chiappella, Beatrice Casadei, et al.
Transplantation and Cellular Therapy
|
January 27, 2025
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study
Federico Stella, Martina Pennisi, Annalisa Chiappella, et al.
Transplantation and Cellular Therapy
|
February 25, 2026
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE Study
Angelica Barone, Federico Stella, Silva Ljevar, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 1, 2025
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee
Gandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Bone Marrow Transplantation
|
October 1, 2025
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee
Gandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Nature Communications
|
May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy
Michael Schneider, Luca Paruzzo, Federico Stella, et al.
Cell
|
March 7, 2026
β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer
Shan Liu, Puneeth Guruprasad, Ranjani Ramasubramanian, et al.
Blood
|
January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies
Alberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Science Translational Medicine
|
February 4, 2026
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells
Ivan J Cohen, Audrey C Bochi-Layec, Jean Lemoine, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Biorxiv : the Preprint Server for Biology
|
February 6, 2026
The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target
Zhiwei Ang, Annette Castro, Luca Paruzzo, et al.
Blood Cancer Discovery
|
July 2, 2024
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Federico Stella, Annalisa Chiappella, Beatrice Casadei, et al.
Transplantation and Cellular Therapy
|
January 27, 2025
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study
Federico Stella, Martina Pennisi, Annalisa Chiappella, et al.
Transplantation and Cellular Therapy
|
February 25, 2026
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE Study
Angelica Barone, Federico Stella, Silva Ljevar, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 1, 2025
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee
Gandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Bone Marrow Transplantation
|
October 1, 2025
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee
Gandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Nature Communications
|
May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy
Michael Schneider, Luca Paruzzo, Federico Stella, et al.
Cell
|
March 7, 2026
β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer
Shan Liu, Puneeth Guruprasad, Ranjani Ramasubramanian, et al.
Blood
|
January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies
Alberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Science Translational Medicine
|
February 4, 2026
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells
Ivan J Cohen, Audrey C Bochi-Layec, Jean Lemoine, et al.
Page
of 7